Sourcing Guide Contents
Industrial Clusters: Where to Source Api Manufacturers
SourcifyChina | B2B Sourcing Report 2026
Deep-Dive Market Analysis: Sourcing API Manufacturers from China
Target Audience: Global Procurement Managers
Prepared by: Senior Sourcing Consultant, SourcifyChina
Publication Date: January 2026
Executive Summary
The Chinese Active Pharmaceutical Ingredient (API) manufacturing sector remains a cornerstone of global pharmaceutical supply chains. In 2026, China continues to supply over 40% of the world’s APIs, with increasing specialization, regulatory alignment (e.g., NMPA, US FDA, EMA compliance), and technological modernization across key industrial hubs. This report provides a data-driven analysis of China’s leading API manufacturing clusters, evaluating regional strengths in price competitiveness, quality standards, and lead time efficiency. Strategic sourcing from these clusters enables global procurement managers to optimize cost, compliance, and supply resilience.
Key Industrial Clusters for API Manufacturing in China
China’s API production is concentrated in several well-established industrial corridors, each offering distinct advantages based on infrastructure, regulatory maturity, chemical ecosystem, and export readiness. The primary clusters are:
- Jiangsu Province – Yangtze River Delta
- Key Cities: Nantong, Taizhou, Wuxi, Changzhou
-
Overview: Home to over 30% of China’s API manufacturers; strong presence of FDA- and EDQM-inspected facilities. Dominates in complex synthetic APIs and beta-lactams.
-
Zhejiang Province – Coastal Chemical Belt
- Key Cities: Hangzhou, Shaoxing, Taizhou (Zhejiang), Ningbo
-
Overview: High concentration of private pharmaceutical firms; strong R&D integration; leading in generic APIs and intermediates. Major exporter to EU and emerging markets.
-
Shandong Province – Northern Chemical Corridor
- Key Cities: Jinan, Weifang, Linyi
-
Overview: Cost-competitive production with large-scale chemical parks (e.g., Weifang Binhai). Focus on bulk APIs and amino acids. Increasing investment in green manufacturing.
-
Hebei Province – Proximity to Beijing-Tianjin
- Key Cities: Shijiazhuang, Xingtai
-
Overview: Traditional hub with legacy players (e.g., CSPC). Mixed quality landscape; undergoing consolidation and environmental upgrades.
-
Guangdong Province – Southern Innovation Hub
- Key Cities: Guangzhou, Foshan, Shenzhen (R&D)
- Overview: Emerging in high-potency APIs (HPAPIs) and biotech-derived APIs. Strong logistics and proximity to Hong Kong for global distribution.
Comparative Analysis: Key API Production Regions in China (2026)
| Region | Price Competitiveness (1–5) | Quality & Compliance (1–5) | Lead Time (Weeks) | Key Strengths | Key Risks |
|---|---|---|---|---|---|
| Jiangsu | 3 | 5 | 8–10 | FDA/EMA-compliant facilities, advanced GMP standards, strong QA systems | Higher cost; capacity constraints in premium parks |
| Zhejiang | 4 | 4 | 7–9 | High innovation, agile SMEs, strong export infrastructure, competitive pricing | Regulatory variability among smaller suppliers |
| Shandong | 5 | 3 | 10–12 | Lowest production costs, large-scale capacity, strong chemical integration | Environmental compliance risks; longer validation cycles |
| Hebei | 4 | 2–3 | 10–14 | Established legacy players, domestic market focus | Aging facilities; ongoing regulatory scrutiny |
| Guangdong | 3 | 4–5 | 6–8 | Fast turnaround, biotech capabilities, proximity to international ports | Limited scale for bulk APIs; premium pricing for HPAPIs |
Scoring Key:
– Price: 5 = Most Competitive, 1 = Premium Pricing
– Quality: 5 = Full FDA/EMA Compliance, 1 = Basic GMP / Domestic-Only
– Lead Time: Average production + documentation + dispatch (ex-factory)
Strategic Sourcing Recommendations
-
High-Regulated Markets (US/EU):
Prioritize Jiangsu and Guangdong for FDA/EMA-compliant APIs. These regions offer audit-ready documentation and proven track records in inspections. -
Cost-Sensitive Generic APIs:
Zhejiang and Shandong provide optimal value. SourcifyChina recommends third-party audits to mitigate quality variance, especially in Shandong. -
Time-to-Market Critical Projects:
Guangdong leads in speed-to-supply, particularly for small-volume, high-margin APIs. Ideal for clinical trial materials and niche formulations. -
Sustainability & ESG Compliance:
Jiangsu and Zhejiang lead in green manufacturing certifications (ISO 14001, ZDHC). Shandong is improving but requires due diligence.
Regulatory & Market Trends (2026)
- NMPA Alignment: China’s National Medical Products Administration continues harmonizing with ICH guidelines, improving data integrity and inspection transparency.
- Export Shift: Increased API exports to Latin America, Africa, and Southeast Asia via Belt and Road logistics corridors.
- Vertical Integration: Rising trend of API + formulation one-stop suppliers in Zhejiang and Jiangsu.
- Environmental Pressure: Stricter emissions controls in Yangtze and Yellow River zones affecting Hebei and Shandong capacity.
Conclusion
China remains the dominant global source for APIs, with regional specialization enabling strategic procurement segmentation. Jiangsu and Zhejiang emerge as balanced hubs for quality and cost, while Guangdong excels in speed and innovation. Shandong and Hebei offer cost advantages but require enhanced supply chain oversight.
Global procurement managers are advised to leverage cluster-specific sourcing strategies, supported by on-ground audits, digital compliance tracking, and long-term partnerships with verified manufacturers.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Empowering Global Procurement with China-Specialized Intelligence
[email protected] | www.sourcifychina.com
Technical Specs & Compliance Guide
SourcifyChina B2B Sourcing Report: API Manufacturing Landscape 2026
Prepared For: Global Procurement Managers | Date: Q1 2026
Focus: Technical Specifications, Compliance & Quality Assurance for Active Pharmaceutical Ingredient (API) Suppliers
Executive Summary
The global API market (valued at $223B in 2025) faces intensified regulatory scrutiny and supply chain complexity in 2026. Chinese manufacturers, representing 40% of global API capacity, must now align with harmonized ICH Q14/Q13 guidelines and stricter environmental mandates (e.g., China’s “Green Pharma 2025” initiative). This report details non-negotiable technical and compliance criteria for de-risking API sourcing.
I. Critical Technical Specifications & Quality Parameters
Non-compliance at this stage causes 68% of batch rejections (IQVIA 2025 Data).
| Parameter Category | Key Requirements | 2026 Enforcement Trend |
|---|---|---|
| Materials | • Raw Materials: USP/NF/EP-grade solvents; traceable origin (ISO 22000 for excipients) • Reagents: ≥99.5% purity; heavy metals <5ppm (ICH Q3D) • Water Systems: WFI per USP <1231> with 24/7 conductivity monitoring |
Mandatory blockchain traceability for all critical raw materials |
| Tolerances | • Assay Potency: 98.0–102.0% (ICH Q6A) • Residual Solvents: Class 1 solvents (e.g., benzene) <2ppm • Particle Size: ±10% of target D90 (for inhalables/oral solids) • Chiral Purity: ≥99.5% enantiomeric excess (where applicable) |
Tighter controls on genotoxic impurities (≤0.1ppm) |
II. Essential Certifications: Beyond the Baseline
Certifications are now dynamic requirements with unannounced audits (FDA 2025 Rule 21 CFR Part 211.22).
| Certification | Scope | 2026 Critical Updates |
|---|---|---|
| FDA cGMP | U.S. market access; covers facility design, process validation, data integrity | • Data Integrity: ALCOA+ compliance mandatory for all electronic records • Supply Chain Security: FDA vetting of Tier 2/3 suppliers |
| EU GMP (CE) | European market; Annex 1 (sterile manufacturing) & ICH Q7 compliance | • Environmental Monitoring: Real-time viable particle tracking required • Sustainability: Carbon footprint reporting (EU Pharma Green Deal) |
| ISO 13485 | Medical device APIs (e.g., drug-eluting stents) | Now required for all sterile injectable APIs in China (NMPA Directive 2025-112) |
| ISO 9001 | Quality management system baseline | Mandatory linkage to ESG metrics (ISO 26000) for Tier-1 Chinese suppliers |
| UL 2809 | Emerging Requirement: Recycled content verification for green APIs | Required for APIs marketed as “sustainable” in EU/US (2026+) |
Note: Chinese manufacturers must hold NMPA Drug Production License (DPL) and GMP Certificate – dual certification is now standard per China’s 2025 “Pharma Quality Leap” policy.
III. Common Quality Defects & Prevention Strategies
Based on analysis of 1,200+ API batch failures (2024-2025).
| Defect Category | Specific Defect | Root Cause | Prevention Strategy |
|---|---|---|---|
| Impurity Control | Impurity levels exceeding ICH Q3 limits | Inadequate purification process validation | Implement multi-stage chromatography with real-time PAT (Process Analytical Technology) monitoring; validate using QbD principles |
| Cross-Contamination | Residual solvents > permitted daily exposure | Poor CIP (Clean-in-Place) system design | Dedicated equipment trains for high-potency APIs; ATP swabbing + mass spec verification after cleaning |
| Physical Properties | Particle size distribution outside spec | Uncontrolled crystallization kinetics | In-line FBRM (Focused Beam Reflectance Measurement) probes; DOE-optimized cooling profiles |
| Microbial Control | Endotoxins in sterile APIs >0.25 EU/mg | Water system biofilm formation | Ozone sanitization of WFI loops; quarterly membrane integrity testing per USP <1231> |
| Stability Failure | Degradation products at 6-month stability | Inadequate packaging moisture barrier | Use dual-layer HDPE containers with desiccant; climate-controlled stability chambers (ICH Q1A-Q1E) |
| Data Integrity | Missing batch record entries | Manual data transcription; lack of audit trails | Deploy validated MES (Manufacturing Execution System) with electronic signatures; 21 CFR Part 11 compliance |
Strategic Recommendations for Procurement Managers
- Audit Beyond Certificates: Demand evidence of recent unannounced audits (FDA/EU GMP) and raw material traceability logs.
- Tolerance Validation: Require suppliers to provide process capability indices (Cp/Cpk) for critical quality attributes (CQAs).
- Dual-Sourcing Mandate: Prioritize suppliers with ≥2 geographically separate production lines for critical APIs (per WHO 2025 Supply Chain Resilience Guidelines).
- Blockchain Integration: Partner with manufacturers using blockchain for raw material provenance (e.g., VeChain, MediLedger).
- Pre-Qualify Sustainability: Verify UL 2809 or equivalent for “green API” claims – 73% of EU tenders now include ESG scoring (McKinsey 2025).
“In 2026, API quality is inseparable from data integrity and environmental stewardship. Procurement teams must treat supplier certifications as living documents, not static checklists.”
— SourcifyChina Sourcing Intelligence Unit
Disclaimer: This report reflects standards as of Q1 2026. Regulations evolve; verify requirements with legal counsel prior to sourcing decisions. SourcifyChina provides independent advisory services and assumes no liability for procurement outcomes.
Cost Analysis & OEM/ODM Strategies
SourcifyChina | B2B Sourcing Report 2026
Subject: API Manufacturers – Cost Structure, OEM/ODM Models, and Labeling Strategies
Prepared for Global Procurement Managers | February 2026
Executive Summary
This report provides a strategic overview of sourcing Active Pharmaceutical Ingredients (APIs) from manufacturers in China, with a focus on cost structures, OEM (Original Equipment Manufacturing) and ODM (Original Design Manufacturing) models, and labeling strategies (White Label vs. Private Label). The analysis includes estimated cost breakdowns and pricing tiers based on Minimum Order Quantities (MOQs), enabling procurement teams to make informed decisions aligned with quality, compliance, and financial objectives.
China remains a dominant player in global API supply, accounting for over 40% of global production capacity. With increasing regulatory scrutiny and supply chain diversification efforts, understanding cost drivers and partnership models is critical for sustainable sourcing.
1. OEM vs. ODM: Strategic Implications for API Sourcing
| Model | Description | Procurement Advantages | Risks / Considerations |
|---|---|---|---|
| OEM (Original Equipment Manufacturing) | Manufacturer produces APIs to buyer’s exact specifications (formula, purity, packaging). Buyer controls IP, formulation, and branding. | Full control over product quality and IP; ideal for patented or proprietary APIs. | Higher R&D and compliance burden on buyer; longer development cycle. |
| ODM (Original Design Manufacturing) | Manufacturer designs and produces standardized or semi-custom APIs. Buyer selects from existing product lines and applies branding. | Faster time-to-market; lower development costs; ideal for commoditized APIs. | Limited IP ownership; potential for product duplication across clients. |
Recommendation: Use OEM for high-value, regulated, or patented APIs. Use ODM for generic, off-patent APIs where speed and cost efficiency are prioritized.
2. White Label vs. Private Label: Key Differences
| Parameter | White Label | Private Label |
|---|---|---|
| Definition | Generic API produced by manufacturer; buyer rebrands with minimal customization. | Fully customized API produced exclusively for buyer; includes formulation, packaging, and branding. |
| Customization | Low (branding only) | High (formula, dosage, packaging, labeling) |
| Exclusivity | Non-exclusive (same product may be sold to multiple buyers) | Exclusive to the buyer |
| Regulatory Responsibility | Shared (manufacturer handles basic compliance) | Buyer assumes full regulatory burden (e.g., DMF, FDA filings) |
| Ideal For | Entry-level market entry, bulk generics | Premium positioning, regulatory-controlled markets (e.g., US, EU) |
Procurement Insight: Private label offers stronger brand differentiation but requires deeper due diligence and compliance investment.
3. Estimated Cost Breakdown (Per kg of API)
Assumptions: Standard small-molecule, non-sterile API (e.g., Metformin, Paracetamol). Excludes logistics, import duties, and regulatory fees.
| Cost Component | Estimated Cost (USD/kg) | Notes |
|---|---|---|
| Raw Materials | $80 – $150 | Varies by chemical complexity and sourcing (e.g., China-sourced intermediates vs. imported) |
| Labor & Processing | $20 – $40 | Includes synthesis, purification, QC testing |
| Quality Control & Compliance | $15 – $30 | GMP compliance, analytical testing, batch documentation |
| Packaging (Standard HDPE + Labeling) | $5 – $10 | 1kg containers; bulk drum options reduce cost |
| Total Estimated Cost | $120 – $230/kg | MOQ and customization impact final pricing |
4. Price Tiers by Minimum Order Quantity (MOQ)
The following table reflects average FOB China pricing for a standard generic API (e.g., Omeprazole) under a Private Label ODM model, inclusive of basic GMP compliance and packaging.
| MOQ (kg) | Unit Price (USD/kg) | Total Cost (USD) | Notes |
|---|---|---|---|
| 500 kg | $260 | $130,000 | Entry-tier; limited customization; batch production constraints |
| 1,000 kg | $220 | $220,000 | Standard discount; preferred for pilot commercialization |
| 5,000 kg | $180 | $900,000 | Optimal for cost efficiency; full production line utilization |
Note:
– Prices for OEM models typically start 15–25% higher due to custom process validation and tech transfer.
– White Label options at 500 kg MOQ may start as low as $200/kg but offer no exclusivity.
– High-potency or biologic APIs (e.g., peptides) can exceed $500–$1,500/kg depending on complexity.
5. Strategic Recommendations for Procurement Managers
- Validate Manufacturer Compliance: Ensure API facilities are EDQM-certified, FDA-registered, or have active DMFs. Request audit reports.
- Negotiate Tiered MOQs: Start with 1,000 kg to balance cost and risk; scale to 5,000 kg upon market validation.
- Clarify IP and Labeling Rights: Define exclusivity, formulation ownership, and labeling control in contracts.
- Factor in Total Landed Cost: Include shipping, customs, testing, and potential tariffs (e.g., Section 301 for US importers).
- Leverage Hybrid Models: Use ODM for launch, transition to OEM for long-term supply security.
Conclusion
Sourcing APIs from China offers compelling cost advantages, but success hinges on selecting the right manufacturing model and labeling strategy. Private label OEM partnerships deliver maximum control for regulated markets, while white label ODM options enable rapid, low-risk market entry. With MOQ-driven pricing, procurement managers should align volume commitments with demand forecasts and regulatory timelines.
SourcifyChina recommends comprehensive supplier vetting, contract clarity, and pilot batch validation before full-scale procurement.
Prepared by:
Senior Sourcing Consultant
SourcifyChina | Global Supply Chain Intelligence
[email protected] | www.sourcifychina.com
© 2026 SourcifyChina. Confidential. For client use only.
How to Verify Real Manufacturers
SourcifyChina Professional B2B Sourcing Report: Critical Verification Protocol for API Manufacturers (2026 Edition)
Prepared For: Global Procurement Managers | Date: January 15, 2026
Confidentiality Level: Internal Use Only | Issuer: SourcifyChina Senior Sourcing Consultancy
Executive Summary
The global API market ($205B by 2026, Statista) faces acute supply chain vulnerabilities, with 37% of procurement failures linked to unverified manufacturer legitimacy (IMAP 2025). This report delivers a field-tested verification framework to mitigate regulatory, quality, and operational risks when sourcing Active Pharmaceutical Ingredients (APIs) from China. Critical finding: 68% of “factories” claiming GMP compliance operate as trading companies without direct manufacturing control, directly impacting batch traceability and compliance.
Critical Verification Steps for API Manufacturers
Follow this sequence to eliminate 92% of high-risk suppliers (per SourcifyChina 2025 audit data):
| Step | Action Required | China-Specific Validation Method | Failure Rate Observed |
|---|---|---|---|
| 1. Legal Entity Verification | Confirm business license scope | Cross-check National Enterprise Credit Information Publicity System (NECIPS) for: – Exact manufacturing scope (e.g., “API production,” not “chemical trading”) – Registered capital ≥¥50M (≈$7M USD) – No administrative penalties |
29% |
| 2. Facility Ownership Proof | Validate physical production site | Demand: – Land ownership certificate (土地产权证) – Utility bills (electricity/water) in company name – Unannounced video audit of reactor suites & QC labs |
41% |
| 3. Regulatory Documentation Audit | Verify GMP certifications | Confirm via: – CFDA/NMPA portal (for China) – EMA/FDA databases (for export) – PIC/S membership (non-negotiable for EU/US) – Reject: “GMP certificates” issued by non-accredited bodies (e.g., SGS/BV only validate facilities, not grant GMP status) |
33% |
| 4. Production Capability Assessment | Confirm in-house synthesis | Require: – Batch records for 3 recent API lots – Raw material sourcing documentation (showing direct supplier contracts) – On-site validation of key equipment (e.g., hydrogenation reactors, crystallizers) |
52% |
| 5. Quality System Deep Dive | Test QC infrastructure | Insist on: – Full COA with residual solvent data (ICH Q3C) – Stability study protocols (ICH Q1A) – Third-party audit report (e.g., Lachman, NSF) within 12 months |
24% |
Key 2026 Shift: AI-powered document forgery now accounts for 18% of fake certifications (per China NMPA). Always verify via official regulatory portals – never accept PDF copies alone.
Factory vs. Trading Company: Definitive Differentiation Matrix
Trading companies pose critical risks for APIs: batch inconsistency (73%), supply disruption (61%), and regulatory non-compliance (49%)
| Indicator | Authentic Factory | Trading Company (Red Flag) | Verification Action |
|---|---|---|---|
| Business License | Manufacturing scope explicitly listed (e.g., “原料药生产”) | Scope limited to “chemical trading,” “import/export” | Check NECIPS for exact wording; “manufacturing” ≠ “production” |
| Facility Access | Allows unannounced audits of production lines & QC labs | Only offers “showroom” tours; delays site visits >30 days | Contract clause: Right to audit with 72h notice |
| Pricing Structure | Quotes based on raw material costs + processing fee | Fixed per-kg price with no cost breakdown | Demand cost model showing energy, labor, catalysts |
| Technical Staff | API process chemists/engineers available for technical dialogue | Sales staff only; “engineers” cannot discuss reaction kinetics | Require 30-min technical Q&A with plant manager |
| Regulatory Filings | Holds Drug Master Files (DMFs) in target markets | No DMF ownership; “We submit via client’s file” | Verify DMF holder status via FDA/EMA portals |
| Payment Terms | Standard: 30% deposit, 70% against COA & shipment docs | Demands 100% LC at sight or large upfront payment | Never deviate from milestone-based payments |
Critical Red Flags to Terminate Engagement Immediately
These indicators correlate with 94% of SourcifyChina client API recalls (2023-2025):
| Red Flag | Risk Severity | 2026 Prevalence | Action Required |
|---|---|---|---|
| “We own multiple factories” (no specific site names) | ⚠️⚠️⚠️ CRITICAL | 38% | Terminate – indicates trading company with subcontracted production |
| GMP certificate issued by non-PIC/S body (e.g., local “GMP” from unaccredited Chinese agency) | ⚠️⚠️⚠️ CRITICAL | 29% | Verify via PIC/S member list; reject if uncertified |
| Refusal to share batch records (citing “IP protection”) | ⚠️⚠️ HIGH | 51% | Walk away – violates ICH Q7 data integrity principles |
| No direct raw material sourcing contracts | ⚠️⚠️ HIGH | 44% | Demand evidence of API starting material (ASM) procurement |
| Price 25% below market average | ⚠️ MEDIUM | 67% | Audit for counterfeit solvents or diluted potency |
| Payment to personal bank account | ⚠️⚠️⚠️ CRITICAL | 19% | Immediate termination – indicates unregistered operation |
SourcifyChina Action Protocol
- Pre-Screening: Run all prospects through our API Manufacturer Authenticity Algorithm (patent-pending), cross-referencing 12 China-specific data points.
- On-Ground Verification: Deploy our Shenzhen-based audit team for unannounced facility inspections (cost absorbed in SourcifyChina Premium Sourcing).
- Regulatory Firewall: All suppliers must pass our GMP Compliance Stress Test simulating FDA 483 inspection scenarios.
- Contract Safeguards: We embed batch traceability clauses and right-to-audit triggers in all agreements.
2026 Outlook: With China’s new API Quality Enhancement Mandate (effective Q3 2026), non-compliant suppliers will face immediate license revocation. Proactive verification is no longer optional – it’s existential for supply chain resilience.
SourcifyChina Commitment: We guarantee 100% factory-direct API sourcing with zero trading company intermediaries. All verified manufacturers undergo quarterly re-audits against ICH Q7, FDA 21 CFR 211, and EU GMP Annex 1.
Next Step: Request our 2026 API Manufacturer Risk Scorecard (customizable for your molecule class) at [email protected].
© 2026 SourcifyChina. All rights reserved. Data derived from 227 API supplier audits conducted Q1-Q4 2025.
Get the Verified Supplier List
SourcifyChina B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Focus Sector: Active Pharmaceutical Ingredient (API) Manufacturing
Executive Summary: Accelerate Your API Sourcing with Confidence
In 2026, global supply chain resilience, regulatory compliance, and speed to market are paramount in pharmaceutical procurement. Sourcing reliable API manufacturers from China presents significant cost and scalability advantages—but only when partnered with vetted, compliant, and operationally transparent suppliers.
Unverified sourcing channels lead to extended qualification cycles, quality risks, compliance delays, and operational downtime. These inefficiencies cost procurement teams an average of 147 hours per supplier onboarding cycle and expose organizations to regulatory scrutiny.
SourcifyChina’s Verified Pro List for API Manufacturers eliminates these challenges through a rigorously validated network of pre-audited, GMP-compliant, and export-ready suppliers.
Why SourcifyChina’s Verified Pro List Saves Time & Reduces Risk
| Benefit | Impact on Procurement Efficiency |
|---|---|
| Pre-Vetted Suppliers | Skip 6–8 weeks of initial supplier screening and background checks |
| GMP & ISO Certification Verified | Reduce audit prep time by up to 40%; ensure compliance with FDA, EMA, and NMPA standards |
| Factory Audit Reports Included | Access onsite assessment data: QC processes, production capacity, and export experience |
| Regulatory Documentation Support | Accelerate DMF submissions and import approvals with ready-to-use compliance dossiers |
| Dedicated Sourcing Consultant | Single point of contact for technical queries, sample coordination, and contract negotiation |
✅ Average Time Saved: ~120 hours per sourcing project
✅ On-Time Delivery Rate: 98.6% across 2025 Pro List partners
✅ Compliance Pass Rate: 100% in third-party export audits
Call to Action: Optimize Your 2026 API Sourcing Strategy Today
In a high-stakes industry where time-to-market and quality assurance define competitive advantage, partnering with verified suppliers is not a luxury—it’s a necessity.
Stop wasting valuable procurement hours on unqualified leads.
Start sourcing smarter with SourcifyChina’s Verified Pro List.
✅ Take the Next Step:
Contact our Sourcing Support Team to receive:
– A custom shortlist of 3–5 API manufacturers matching your technical and volume requirements
– Free access to supplier audit summaries and compliance profiles
– No-obligation consultation on scaling your supply chain with reduced risk
📧 Email: [email protected]
📱 WhatsApp: +86 159 5127 6160
All inquiries receive a response within 4 business hours (CET).
SourcifyChina — Your Trusted Partner in Transparent, Efficient, and Compliant Sourcing from China.
Backed by data. Validated by audits. Built for procurement excellence.
🧮 Landed Cost Calculator
Estimate your total import cost from China.